An interventional study of Healthy plant-based diet (healthy-PBD) and Potassium-restricted plant-based diet in Hyperkalemia and Chronic Kidney Disease (Stages 4 and 5), sponsored by Karolinska Institutet. Not yet recruiting at 1 site in Sweden. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment
For many years, people with moderate to advanced chronic kidney disease (CKD) have been advised to limit their intake of potassium, a mineral found in many foods such as fruit, vegetables, legumes, whole grains, and nuts. The reason for this has been the risk of hyperkalemia, a condition in which the potassium level in the blood becomes too high and can be dangerous. In recent years, however, this view has been questioned. New research suggests that the link between potassium in food and high potassium levels in the blood may not be as clear as previously thought. People who follow a strict potassium-restricted diet experience a lower quality of life and less satisfaction with their dietary treatment. At the same time, they miss out on the health benefits of eating a varied and nutritious diet.
Today, many experts advocate a more individualized approach to potassium intake: instead of generally restricting potassium, the goal should be to maintain normal potassium levels in the blood, while encouraging a healthy diet. However, this message is not always clear in healthcare, and many people therefore continue to avoid potassium-rich foods altogether. The result is that they eat fewer natural ingredients and instead consume more processed and ultra-processed foods. Such foods can be more harmful, partly because they often contain potassium additives that are absorbed effectively by the body and their quantities are not reported in the nutritional label. This "hidden" potassium can contribute more to high potassium levels in the blood than the potassium that occurs naturally in plant-based foods. In addition, potassium from whole plant-based foods is absorbed more slowly, partly due to its fiber content.
Plant-based diets may also have other positive effects for people with kidney disease: they can contribute to reduced blood acidity, known as metabolic acidosis, healthier gut flora, lower levels of inflammation, and reduced phosphorus intake. Together, these factors can counteract several of the metabolic complications associated with kidney disease.
In a previous study, our research group showed that even patients with advanced kidney disease (CKD stage 4-5) and already elevated potassium levels could follow a healthy plant-based diet if they also used a potassium-binding drug (sodium zirconium cyclosilicate, SZC). This enabled them to eat more fruit, vegetables, and legumes, while also experiencing improved quality of life. The current study builds on these results and is planned as a pilot study in which patients with moderate to advanced kidney disease, but who are not yet being treated with dialysis, are assigned to two different dietary strategies for six months:
The main purpose is to investigate whether the healthy plant-based diet leads to more or more severe cases of hyperkalemia than the restricted diet. Our hypothesis is that potassium levels may increase slightly in the group with a liberal diet, but not to dangerous levels. The study will also examine secondary outcomes, such as quality of life, satisfaction with treatment, and how well patients accept the diet. In addition, taste experiences will be tested with taste strips (sweet, sour, salt, bitter and umami) before and after the intervention in both groups. If this pilot study shows that a healthier and less restrictive diet is safe, it could pave the way for a larger study investigating the long-term metabolic effects of a plant-based diet in kidney care.
The overall aim of the project is to investigate whether a liberal plant-based diet, rich in fruit, vegetables, legumes, whole grains, and nuts, can be recommended to patients with mild to advanced kidney disease without leading to hyperkalemia. Traditionally, dietary advice for chronic kidney disease (CKD) has focused on potassium restriction, which has led to reduced intake of healthy foods and thereby poorer diet quality. This project aims to challenge this view by shifting the focus from potassium content itself to overall diet quality, with a particular focus on patient-centered outcomes such as safety, quality of life, treatment satisfaction, acceptance and sensory effects (taste sensitivity).
The study addresses an important knowledge gap in current nutritional guidelines for patients with kidney disease. The latest recommendations emphasize individualization and maintaining normal potassium levels, rather than general restrictions, but this advice is based on limited evidence and has not yet been tested in longer clinical studies.
This project is therefore limited to conducting a 6-month pilot study with a randomized controlled design. The focus is primarily on safety outcomes, especially the occurrence of hyperkalemia, and secondarily on patient-reported outcomes, dietary acceptance, and taste experience. Metabolic effects are not examined in detail in this study, but the results will form the basis for a larger follow-up study with a broader focus on long-term metabolic and clinical benefits.
The project's main scientific question is whether it is safe for patients with moderate to advanced kidney disease to eat a plant-based diet without restricting potassium-rich foods. In current clinical practice, patients are advised to avoid fruits, vegetables, legumes, and nuts, despite the fact that an increasing number of studies suggest that potassium from whole plant-based foods does not necessarily lead to dangerously high potassium levels in the blood. The study defines the following outcome measures:
Primary outcome: Time to first hyperkalemia event (plasma potassium > 5.5 mmol/L). Number of hyperkalemia events in the two groups during the 22-26 weeks following randomization. Potassium as a continuous variable.
Secondary endpoints: Patient-reported endpoints, quality of life (RAND-36 questionnaire) and satisfaction with treatment. Laboratory markers: inflammation, kidney function, acid-base balance, uremic toxins, vitamin K, and gut flora-related markers. Nutrition-related factors: body composition (measured using bioelectrical impedance), anthropometry, dietary intake, and taste test (sweet, sour, salt, bitter and umami). Dietary compliance: structured questionnaire on intake and 24-hour urine collection for potassium excretion.
This study is designed as a pilot study with a parallel randomized controlled trial (RCT) design with a duration of 22-26 weeks (approximately 6 months). The study will include adult participants (age 20-85) with moderate to advanced CKD, defined as estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m², who are not yet being treated with dialysis nor have undergone kidney transplantation. Individuals with untreated comorbidities or conditions that may affect study participation will be excluded.
Randomization and intervention
Participants will be randomly assigned in a 1:1 ratio to one of two groups:
Both groups will receive individually tailored dietary counselling from a dietitian at baseline and during follow-up visits. Counselling will cover portion sizes, meal composition, and strategies for adhering to the assigned diet. Participants will also receive written dietary advice and food lists.
Study procedures and visits Participants will attend study visits at baseline, 4 weeks, 12 weeks, and 22-26 weeks. The following will be performed at each visit:
Participants are instructed to contact the study team if they experience symptoms that may indicate hyperkalemia, such as muscle weakness or palpitations. If hyperkalemia (p-potassium > 5.5 mmol/L) is detected, adequate medical treatment will be provided, and continued participation in the study will be reconsidered for safety reasons.
Data collection All laboratory analyses will be performed at accredited hospital laboratories according to standardized methods with internal and external quality control. Dietary questionnaires will be validated against urinary potassium excretion. Quality of life and satisfaction questionnaires are validated versions in Swedish. Taste strips will be used under standardized conditions.
To ensure data reliability, all study data will be collected by personnel trained in standardized procedures. Randomization will be computer-generated with concealed allocation. Data entry will be double-checked and deviations verified against source material.
Surveys and interviews The structured dietary surveys will include questions about the frequency and portion size of selected food groups, adherence to prescribed portions, and barriers to following the diet. The survey on treatment satisfaction will include questions about perceived safety, trust in dietary advice, and willingness to continue with the diet after the end of the study. The responses will be analyzed descriptively and compared between groups to identify differences in acceptance and adherence.
Time commitment for participants Each study visit is expected to take approximately 60-90 minutes and will include blood and urine sampling, anthropometry, surveys, and dietary counselling. Participants will also be asked to fill in the dietary records at home and collect 24-hour urine samples at predetermined time points.
The entire study will be conducted in Sweden. All recruitment, intervention, laboratory analyses and follow-up will take place at participating Swedish nephrology clinics.
Exclusion Criteria
Other: Healthy plant-based diet (healthy-PBD)
Other: Potassium-restricted plant-based diet
Healthy plant-based diet (healthy-PBD): A liberal plant-based diet that includes fruits, vegetables, legumes, whole grains, and nuts, with no specific restrictions on potassium.
Potassium-restricted plant-based diet (restricted-PBD): A plant-based diet with restrictions on potassium-rich foods, which corresponds to current standard advice for patients with CKD.
Number of hyperkalemia (plasma potassium >5.5 mmol/L) events in the two groups
Hyperkalemia is defined as plasma potassium \> 5.5 mmol/L. The number of hyperkalemia events, as well as the time to the event, will be registered.
Time frame: for 26 weeks following randomization
Quality of life (RAND-36 questionnaire - score 0 to 100)
Validated for patients with CKD in Sweden - Higher scores reperesent better quality of life
Time frame: for 26 weeks following randomization
Renal Treatment Satisfaction Questionnaire - score 0 to 6
Validated for patients with CKD in Sweden. Comprised of 13 items, each item is scored by the patient from 0 to 6. The higher the score, the higher the satisfaction with the treatment.
Time frame: for 26 weeks following randomization
C-reactive protein (mg/L)
C-reactive protein (mg/L) assessed as a continuous variable
Time frame: for 26 weeks following randomization
Interleukin 6 (pg/mL)
Interleukin 6 (pg/mL) assessed as continous variable
Time frame: for 26 weeks following randomization
Glomerular filtration rate (ml/min/1.73 m2)
Assessed by the Malmö-Lund equation, using serum creatinine (μmmol/L)
Time frame: for 26 weeks following randomization
Albumin/creatinine ratio (spot urine) (mg/g)
Albumin/creatinine ratio (spot urine)
Time frame: for 26 weeks following randomization
24-hour urinary creatinine excretion (mg/L)
24-hour urinary creatinine excretion
Time frame: for 26 weeks following randomization
Serum creatinine (µmol/L)
Serum creatinine (µmol/L)
Time frame: for 26 weeks following randomization
Plasma carbon dioxide (mmol/L)
Plasma carbon dioxide (mmol/L)
Time frame: for 26 weeks following randomization
Plasma Trimethylamine N-oxide (TMAO) (ng/mL)
Trimethylamine N-oxide (TMAO) (ng/mL)
Time frame: for 26 weeks following randomization
Plasma p-Cresyl sulfate (ng/mL)
p-Cresyl sulfate (ng/mL)
Time frame: for 26 weeks following randomization
Plasma Indoxyl sulfate (ng/mL)
Indoxyl sulfate (ng/mL)
Time frame: for 26 weeks following randomization
Vitamin K
dp-ucMGP (pmol/L)
Time frame: for 26 weeks following randomization
Blood DNA microbial
Biomarkers linked to the gut microbiota measured in blood samples
Time frame: for 26 weeks following randomization
Lean body mass (kg)
Assessed by Bioelectrical impedance
Time frame: for 26 weeks following randomization
Body weight (kg)
Assessed with an electronic scale
Time frame: for 26 weeks following randomization
Potassium intake (mg/day)
Assessed by 24 hour food recall
Time frame: for 26 weeks following randomization
Taste perception of salt (scale 1 to 4)
It will be assessed by taste strips (salt). A higher score denotes higher perception.
Time frame: for 26 weeks following randomization
Dietary compliance
Structured questionnaire on intake
Time frame: for 26 weeks following randomization
24-hour potassium excretion in urine (mmol/day)
Will be used to assess dietary compliance to the intake of potassium
Time frame: for 26 weeks following randomization
Plasma potassium as a continuous variable
Changes in plasma potassium (mmol/L) will be followed in both groups.
Time frame: 26 weeks following the randomization
Height (cm)
Assessed with a stadiometer in cm
Time frame: 26 weeks after the randomization
Taste perception of sweet (scale 1 to 4)
Assessed by taste strips (sweet). A higher score denotes higher perception.
Time frame: 26 weeks after the randomization
Taste perception to sour (scale 1 to 4)
Assessed by taste strips (sour). A higher score denotes higher perception.
Time frame: 26 weeks followed the randomization
Taste perception of bitter (scale 1 to 4)
Assessed by taste strips (bitter). A higher score denotes higher perception.
Time frame: 26 weeks followed the randomization
Plan to share: Undecided — We can share upon requirement and justification on the purpose for sharing the data.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Karolinska Institutet